FDA records linked by MedtechLedger show one premarket notification tied to OMRON Healthcare, Inc.: K261929, an upper arm blood pressure monitor identified as BP7155D. The filing sits in the cardiovascular advisory committee area under product code DXN, and the agency recorded a substantially equivalent decision. The manufacturer’s own published pages address clinical validation and product comparison for its blood pressure monitors, which places the filing in the context of a documented monitor line rather than an isolated submission. [1][2][5]

The documented 510(k) record

K261929 was received by FDA on June 9, 2026, and decided on September 10, 2026, with decision code SESE, described as substantially equivalent. The applicant of record is OMRON Healthcare, Inc., and the device name is Upper Arm Blood pressure monitor (BP7155D). The record lists product code DXN, regulation number 870.1130, device class 2, and the cardiovascular advisory committee. The clearance type is recorded as Special, the third-party flag as N, and the statement or summary field as Summary. [1][5]

The filing address on the FDA record is 2895 Greenspoint Pkwy., Suite 100, Hoffman Estates, IL 60169. That address is a filing detail, not a statement of corporate headquarters. The record also carries a contact name and a registration number field populated with a long list of establishment identifiers, which the record does not resolve into a single manufacturing site. [1]

Product classification context

The FDA record classifies the device under the non-invasive blood pressure measurement system device name, with regulation number 870.1130 and device class 2. A separate FDA-derived index entry for K261929 places the record under 21 CFR 870.1130, product code DXN, within the cardiovascular hierarchy, and repeats the September 10, 2026 decision date and the SESE decision. [1][5]

The FDA 510(k) database page for K261929 is the agency’s public premarket notification interface; its page metadata shows a last-updated date of November 16, 2026. The page itself does not add device-specific detail beyond the database record. [2]

Manufacturer-published validation and product pages

OMRON Healthcare’s published clinical validation page states that clinical validation supports product quality and that every model of its blood pressure monitors is made to meet stated standards of precision and reliability. The same page references the US Blood Pressure Validated Device Listing (VDL). These are the manufacturer’s own claims about its validation approach, published on its website. [4]

The manufacturer’s site also carries a blood pressure monitor comparison chart page for upper arm devices, alongside navigation to clinical validation, the OMRON connect app, and a Going for Zero section. The comparison page does not, in the retrieved text, enumerate model specifications. [6]

A notice published on OMRON Healthcare pages warns that counterfeit products appearing to be from OMRON have been sold online, that such products can pose health risks, and that purchases should be made from reputable, authorized resellers. The notice is the manufacturer’s own communication to customers. [3][6]

What the record does and does not establish

The collection represented here contains one linked record, a 510(k), with a decision count of one SESE. That count describes the linked filings as of the snapshot date and is not a measure of total company sales, total product portfolio, or safety performance. No recall records appear in the linked sample. [1]

The record establishes a cleared premarket notification for a named upper arm monitor model. It does not establish commercial availability, pricing, retail channels, or clinical performance results for BP7155D, and the retrieved manufacturer pages do not provide model-level validation results for that device. [1][4]